This month, we are including a recent response to our question under discussion. In addition, please take a look at this month’s new question under discussion.

James M. Irwin, MD, is located at St. Joseph’s Hospital in Tampa, Florida. In this interview, he discusses his experiences using cryoablation.

In this monthly question and answer section, provided by Reliant Pharmaceuticals, we spoke with Dr. Ganz about his pharmacological approach for the management of atrial fibrillation patients.

Our colleagues in other parts of the hospital think the EP lab is boring because it is such a “cerebral” place. You have to use your head. You have to do a lot of thinking, a lot of measurement. However, after three years here, we still learn something new every day we do a case. Recently, we have added the EnSite^® System from Endocardial Solutions (ESI), which brings a whole new dimension to our jobs and the care we provide.

Background: PAH Problem Idiopathic pulmonary arterial hypertension is a rare disease with about 2–3 newly diagnosed cases per million people per year in Europe and the US. Medical therapy is targeted at reduction of pulmonary pressure and resistance. Approved therapies such as endothelin antagonists or prostenoids are complex and expensive. Prior to treatment, the patient’s pulmonary vasodilator response to prostacyclin or nitric oxide is assessed during invasive monitoring.

Recent advances in implantable cardioverter-defibrillator (ICD) devices, including those with cardiac resynchronization therapy, have been described. In this article, we will describe a case report in which the patient met the criteria for cardiac resynchronization therapy and received a recently released biventricular ICD.

In this month’s “10-Minute Interview”, Dr. James McClelland describes his background in electrophysiology. Sacred Heart Medical Center, a 432-bed hospital, is the largest between Portland, Oregon and San Francisco, California.

This article is part of a three-part program on Microvolt T-Wave Alternans, which was put together by Cambridge Heart, Inc. In this next installment, Dr. Daniel Bloomfield will provide his presentation on Microvolt T-Wave Alternans in Congestive Heart Failure/MADIT II patients.

In this article, author Dr. Olshansky discusses the VITALITY AVT INTRINSIC RV Study, which has the largest number of ICD patients compared to any other ICD trial to date. It is also considered the fastest enrolling ICD study ever conducted.